A recent randomized clinical trial revealed that metformin does not significantly reduce the duration of COVID-19 symptoms in low-risk outpatients. Conducted with 2991 participants aged 30 and older across 90 US sites from September 2023 to May 2024, the study reported similar median recovery times of 9 days for metformin and 10 days for placebo. While metformin was well tolerated, the study found no significant differences in health outcomes or safety events, indicating the need for further investigation into its effects on COVID-19.

Source: JAMA Internal Medicine